Jonathan Jay Mazelsky - Feb 8, 2023 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
President & CEO, Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Stock symbol
IDXX
Transactions as of
Feb 8, 2023
Transactions value $
$0
Form type
4
Date filed
2/10/2023, 04:02 PM
Previous filing
Nov 16, 2022
Next filing
Feb 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IDXX Common Stock 70.8K Feb 8, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award +21.3K 21.3K Feb 8, 2023 Common Stock 21.3K $497.43 Direct F2, F6
transaction IDXX Premium Non-Qualified Stock Option (right-to-buy) Award +12.2K 12.2K Feb 8, 2023 Common Stock 12.2K $572.04 Direct F3, F6
transaction IDXX Incentive Stock Option (right-to-buy) Award +201 201 Feb 8, 2023 Common Stock 201 $497.43 Direct F4, F6
transaction IDXX Restricted Stock Unit Award +4.4K +44.02% 14.4K Feb 8, 2023 Common Stock 4.4K Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 18 shares purchased under the Issuer's Employee Stock Purchase Plan on December 31, 2022.
F2 Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024.
F3 Grant of option at a 115% premium to the closing price of Issuer common stock on the NASDAQ Global Select Market on February 8, 2023 to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2024.
F4 Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2027.
F5 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024.
F6 Not applicable.